Involvement of opioid receptors in the antinociception produced by intracerebroventricularly administered spantide in mice

Add time:09/24/2019    Source:sciencedirect.com

The antinociceptive effect of intracerebroventricularly (i.c.v.) administered [D-Arg1, D-Trp7,9, Leu11]-substance P (spantide), a non-selective tachykinin antagonist, was examined using the mouse formalin test. Licking behaviour induced by 2% formalin solution in the hindpaw of mice had two peaks, 0–5 min (first phase) and 10–30 min (second phase). I.c.v. spantide produced a dose-dependent antinociception during the first and second phases. The ID50 values were 2.95 (1.59-5.46) nmol for the first phase and 2.87 (1.49-5.52) nmol for the second phase. The antinociceptive effect in the first phase, but not in the second phase produced by spantide was antagonized by pretreatment with naloxone (1.0 mg/kg, i.p.), an opioid receptor antagonist. An opioid binding study using [3H]naloxone revealed that spantide was able to inhibit [3H]naloxone binding to mouse brain membrane preparations. These results suggest that opioid receptor systems in the mouse brain are involved in spantide-induced antinociception during the first phase, but not during the second phase of the formalin-induced nociceptive behaviour.

We also recommend Trading Suppliers and Manufacturers of R(-)-METHADONE HYDROCHLORIDE OPIOID AGON IST (cas 125-58-6). Pls Click Website Link as below: cas 125-58-6 suppliers

Prev:Reversal by β-funaltrexamine and 16-methyl cyprenorphine of the antinociceptive effects of opioid agonists in the mouse and guinea-pig
Next:Differential effects of μ and κ opioid analgesics on cerebral glucose utilization in the rat)